MUC1-based structures are used as targets for cancer immunotherapy (Martínez-Sáez et al., 2017) and antibodies against ML-proteins are employed to discriminate T. cruzi lineages and to diagnose Chagas disease (Bhattacharyya et al., 2014). This evidence concerns the gene MUC1 and cancer.